Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: This study aimed to develop and validate internally a clinical predictive model, for predicting myasthenic crisis within 30 days after thymectomy in patients with myasthenia gravis.

Methods: Eligible patients were enrolled between January 2015 and May 2019. The primary outcome measure was postoperative myasthenic crisis (POMC). A predictive model was constructed using logistic regression and presented in a nomogram. The area under the receiver operating characteristic curve (AUC) was calculated to examine the performance. The study population was divided into high- and low-risk groups according to Youden index. Calibration curves with 1000 replications bootstrap resampling were plotted to visualize the calibration of the nomogram. Decision curve analyses (DCA) with 1000 replications bootstrap resampling were performed to evaluate the clinical usefulness of the model.

Results: A total of 445 patients were enrolled. Five variables were screened including thymus imaging, onset age, MGFA classification, preoperative treatment regimen, and surgical approach. The model exhibited moderate discriminative ability with AUC value 0.771. The threshold probability was 0.113, which was used to differentiate between high- and low-risk groups. The sensitivity and specificity were 72.1% and 77.1%, respectively. The high-risk group had an 8.70-fold higher risk of POMC. The calibration plot showed that when the probability was between 0 and 0.5, the deviation calibration curve of the model was consistent with the ideal curve.

Interpretation: This nomogram could assist in identifying patients at higher risk of POMC and determining the optimal surgical time for these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109272PMC
http://dx.doi.org/10.1002/acn3.51752DOI Listing

Publication Analysis

Top Keywords

myasthenic crisis
12
postoperative myasthenic
8
predictive model
8
patients enrolled
8
high- low-risk
8
low-risk groups
8
1000 replications
8
replications bootstrap
8
bootstrap resampling
8
higher risk
8

Similar Publications

Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobulin (IVIg) in IMC management. In this retrospective cohort study, we analyzed 51 acetylcholine receptor antibody-positive (AChR-Ab+) IMC patients who received either efgartigimod (n ​= ​30) or IVIg (n ​= ​21) from June 2023 to November 2024.

View Article and Find Full Text PDF

Congenital myasthenic syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by defects in neuromuscular transmission. Unlike autoimmune myasthenia gravis, CMS typically presents in childhood with variable severity and symptoms, and does not involve autoantibodies. This report presents the management of a primigravida diagnosed with CMS who was generally stable on pyridostigmine therapy but experienced a severe exacerbation during pregnancy.

View Article and Find Full Text PDF

Zilucoplan in myasthenic crisis refractory to conventional treatment: a report of two cases.

Acta Neurol Belg

September 2025

Hôpital de la Pitié-Salpêtrière, Médecine Intensive Réanimation à orientation neurologique, Sorbonne Université, AP-HP. Sorbonne Université, 47-83, Bd de l'hôpital, 75013, Paris, France.

View Article and Find Full Text PDF

Background: Thymoma is a malignant tumor originating from the thymic epithelium and can be associated with over 100 paraneoplastic syndromes (PNSs). Due to the low incidence of thymoma and the relative rarity of alopecia areata (AA) as an associated autoimmune disease, patients with thymoma combined with AA are relatively uncommon in clinical practice. As a result, the clinicopathological features and pathogenesis of such patients have been rarely investigated.

View Article and Find Full Text PDF